kingrichards
04-13-2009, 09:34 AM
Sinobiopharma Inc. (SNBP)
Currently $0.64
SNBP is a fully integrated biotechnology company in China, engaged in the research and development, manufacture and marketing of biopharmaceutical products.
SNBP has three products currently being marketed: Clindamycin, an antibiotic launched in 2005; Cisatracurium Besylate, a skeletal muscle relaxant, launched in 2006; and L-alanyl-L-glutamine, for parenteral (intravenous) nutrition, launched in 2007.
SNBP's products being developed in the pipeline include: Eplerenone, an anti-hypertensive that has a formulation with fewer side effects and lower cost than Chinese competitors; Memantine, a treatment for Alzheimer's which received SFDA approval for Phase II Clinical Trials and could be one of the first to launch in the Chinese market; and Perindropil, an anti-hypertensive, the world's first capsule formulation and latest generation of the drug.
SNBP's flagship product, Cisatracurium Besylate, is the world's first to be stored at room temperature, is safer and more effective than other relaxants, and costs only 15% of Nimbex, GSK's patented version that goes off patent in the U.S. in 2010.
SNBP's Cisatracurium Besylate captured 80% of the Chinese market within 14 months of launch.
SNBP has a proven commercialization record in China with a nationwide sales network that distributes its products in 30 provinces and key major cities.
SNBP has their own 30,000 sq. meter SFDA GMP-certified production facilities which employs over 80 people and is located in the Nantong Economic and Technology Development Zone on the Yangtze River about a one hour drive east of Shanghai, and has an over 3,000 sq. meter clean room.
SNBP is certified for the manufacture of active pharmaceutical ingredients, solid dose and injectable drugs. SNBP has a large scale capacity for bottling, freeze-drying, tablet and capsule production that can accommodate substantial anticipated growth from key products.
I will have more information on SNBP later today! China is the world's fastest growing pharmaceutical market so be sure to research SNBP immediately!
Currently $0.64
SNBP is a fully integrated biotechnology company in China, engaged in the research and development, manufacture and marketing of biopharmaceutical products.
SNBP has three products currently being marketed: Clindamycin, an antibiotic launched in 2005; Cisatracurium Besylate, a skeletal muscle relaxant, launched in 2006; and L-alanyl-L-glutamine, for parenteral (intravenous) nutrition, launched in 2007.
SNBP's products being developed in the pipeline include: Eplerenone, an anti-hypertensive that has a formulation with fewer side effects and lower cost than Chinese competitors; Memantine, a treatment for Alzheimer's which received SFDA approval for Phase II Clinical Trials and could be one of the first to launch in the Chinese market; and Perindropil, an anti-hypertensive, the world's first capsule formulation and latest generation of the drug.
SNBP's flagship product, Cisatracurium Besylate, is the world's first to be stored at room temperature, is safer and more effective than other relaxants, and costs only 15% of Nimbex, GSK's patented version that goes off patent in the U.S. in 2010.
SNBP's Cisatracurium Besylate captured 80% of the Chinese market within 14 months of launch.
SNBP has a proven commercialization record in China with a nationwide sales network that distributes its products in 30 provinces and key major cities.
SNBP has their own 30,000 sq. meter SFDA GMP-certified production facilities which employs over 80 people and is located in the Nantong Economic and Technology Development Zone on the Yangtze River about a one hour drive east of Shanghai, and has an over 3,000 sq. meter clean room.
SNBP is certified for the manufacture of active pharmaceutical ingredients, solid dose and injectable drugs. SNBP has a large scale capacity for bottling, freeze-drying, tablet and capsule production that can accommodate substantial anticipated growth from key products.
I will have more information on SNBP later today! China is the world's fastest growing pharmaceutical market so be sure to research SNBP immediately!